Historical review: Cytokines as therapeutics and targets of therapeutics.

[1]  H. Hengartner,et al.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis , 2004, Rheumatology International.

[2]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.

[3]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[4]  D. Goodin,et al.  Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.

[5]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[6]  J. Tavel,et al.  Therapeutic use of interleukin-2 in HIV-infected patients. , 2002, Current opinion in pharmacology.

[7]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.

[8]  D. Pisetsky,et al.  Progress in the treatment of rheumatoid arthritis. , 2001, JAMA.

[9]  L. Steinman.  Blockade of gamma interferon might be beneficial in MS , 2001, Multiple Sclerosis.

[10]  M. Feldmann,et al.  Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. , 2001, Arthritis and rheumatism.

[11]  Roland Martin,et al.  Immunotherapy of multiple sclerosis: Where are we? Where should we go? , 2001, Nature Immunology.

[12]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[13]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[14]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[15]  T. Waldmann,et al.  Advances in interleukin 2 receptor targeted treatment , 2000, Annals of the rheumatic diseases.

[16]  H. Genant,et al.  A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. , 2000, Arthritis and rheumatism.

[17]  F. Breedveld,et al.  The effects of interferon-β treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis , 2000 .

[18]  M. Feldmann,et al.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[19]  F. Breedveld,et al.  The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[20]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[21]  F. Breedveld,et al.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.

[22]  O. Stuve,et al.  Interferon beta in the treatment of multiple sclerosis , 1998, Neurology.

[23]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[24]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[25]  R. P. Kinkel,et al.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis , 1997, Neurology.

[26]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[27]  M. Brunda,et al.  Interferons and Other Cytokines , 1997 .

[28]  R. Kinkel,et al.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997. , 1997, Neurology.

[29]  F. Breedveld,et al.  Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[30]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[31]  J. Woody,et al.  In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. , 1996, Journal of immunology.

[32]  M. Feldmann,et al.  Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. , 1995, European cytokine network.

[33]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[34]  G. Kollias,et al.  The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. , 1995, Cytokine.

[35]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[36]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[37]  A. Thomson.  The cytokine handbook , 1994 .

[38]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[39]  R. Knobler,et al.  Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. , 1993, Journal of interferon research.

[40]  G. Tytgat,et al.  Tumour-necrosis-factor antibody treatment in Crohn's disease , 1993, The Lancet.

[41]  E. Wardle.  Cytokines: an overview. , 1993, The European journal of medicine.

[42]  R. Gentz,et al.  Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. , 1992, Immunology.

[43]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Feldmann,et al.  Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. , 1992, Arthritis and rheumatism.

[45]  M. Palladino,et al.  Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Feldmann,et al.  TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.

[47]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[48]  M. Feldmann,et al.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[49]  M. Turner,et al.  Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α , 1991, European journal of immunology.

[50]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[51]  M. Feldmann,et al.  Cytokine production in the rheumatoid joint: implications for treatment. , 1990, Annals of the rheumatic diseases.

[52]  A. Cerami,et al.  Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis , 1989, The Journal of experimental medicine.

[53]  E. A. Havell.  Evidence that tumor necrosis factor has an important role in antibacterial resistance. , 1989, Journal of immunology.

[54]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[55]  V. Kindler,et al.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection , 1989, Cell.

[56]  M. Feldmann,et al.  Mechanism of immune complex‐mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon‐γ and tumor necrosis factor‐α , 1989, European journal of immunology.

[57]  M. Feldmann,et al.  Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-gamma and tumor necrosis factor-alpha. , 1989, European journal of immunology.

[58]  T. Waldmann,et al.  Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. , 1988, Blood.

[59]  M. Turner,et al.  Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. , 1988, Clinical and experimental immunology.

[60]  G. Nuki,et al.  Tumour necrosis factor in synovial exudates. , 1988, Annals of the rheumatic diseases.

[61]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[62]  T. Taniguchi,et al.  Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. , 1988, Clinical and experimental immunology.

[63]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[64]  L. Sachs.  The molecular control of blood cell development. , 1987, Science.

[65]  R. Herndon,et al.  MULTICENTRE DOUBLE-BLIND STUDY OF EFFECT OF INTRATHECALLY ADMINISTERED NATURAL HUMAN FIBROBLAST INTERFERON ON EXACERBATIONS OF MULTIPLE SCLEROSIS☆ , 1986, The Lancet.

[66]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[67]  B. Aggarwal,et al.  Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin , 1985, International journal of cancer.

[68]  J. Vilček,et al.  Monoclonal antibodies as structural probes for oligomeric human interferon-gamma. , 1985, Journal of interferon research.

[69]  J. Vilček,et al.  Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[70]  B. Aggarwal,et al.  Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin , 1984, The Journal of experimental medicine.

[71]  S. Durum,et al.  The pyrogenic and mitogenic actions of interleukin-1 are related , 1983, Nature.

[72]  C. Berry.  Intrathecal interferon for multiple sclerosis. , 1982, Science.

[73]  K. Cantell,et al.  Adjuvant interferon treatment of human osteosarcoma. , 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[74]  T. Taniguchi,et al.  Molecular cloning of human interferon cDNA. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[75]  I. Gresser.  On the varied biologic effects of interferon. , 1977, Cellular immunology.

[76]  I. Gresser,et al.  Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Vilček,et al.  Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications. , 1976, The Journal of infectious diseases.

[78]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[79]  S. Skurkovich,et al.  The probable role of interferon in allergy. , 1975, Annals of allergy.

[80]  K. Cantell,et al.  Clinical and laboratory investigations on man: systemic administration of potent interferon to man. , 1973, Journal of the National Cancer Institute.

[81]  W. Howson,et al.  “Lymphokines”: Non-Antibody Mediators of Cellular Immunity generated by Lymphocyte Activation , 1969, Nature.

[82]  I. Gresser,et al.  Increased survival in mice inoculated with tumor cells and treated with interferon preparations. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[83]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.

[84]  D. Metcalf,et al.  The growth of mouse bone marrow cells in vitro. , 1966, The Australian journal of experimental biology and medical science.

[85]  J. David,et al.  DELAYED HYPERSENSITIVITY IN VITRO. I. THE SPECIFICITY OF INHIBITION OF CELL MIGRATION BY ANTIGENS. , 1964, Journal of immunology.

[86]  J. David,et al.  DELAYED HYPERSENSITIVITY IN VITRO. II. EFFECT OF SENSITIVE CELLS ON NORMAL CELLS IN THE PRESENCE OF ANTIGEN. , 1964, Journal of immunology.

[87]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[88]  I. L. Bennett,et al.  Studies on the pathogenesis of fever. II. Characterization of fever-producing substances from polymorphonuclear leukocytes and from the fluid of sterile exudates. , 1953 .

[89]  V. Hamburger,et al.  A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo , 1953 .